Folic Acid-Functionalized β-Cyclodextrin for Delivery of Organelle-Targeted Peptide Chemotherapeutics in Cancer DOI

Hae Won Ok,

Seongeon Jin,

Gaeun Park

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(9), P. 4498 - 4509

Published: July 29, 2024

Recent emphasis on the design of drug delivery systems typically involves effective transport a pharmaceutical substance to disease site with desired therapeutic efficacy and minimal cytotoxicity. Organelle-targeted peptides have become an integral part designing important class prodrug/prodrug assemblies for new supramolecular therapeutics owing their favorable biocompatibility, synthetic ease, tunability aggregation behavior, functionalization site-specificity. However, it is still limited due low selectivity. We designed folic acid-functionalized β-cyclodextrin (FA-CD) as platform specific selective organelle-targeted (such microtubule, lysosome, mitochondria) peptide chemotherapeutics folate receptor (FR) overexpressing cancer cell lines. Low toxicity was found FA-CD inclusion complex in FR-negative normal cells, but superior inhibition tumor growth no vivo xenograft model.

Language: Английский

ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine DOI

Zhengyang Quan,

Sa Wang,

Huanhuan Xie

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 15, 2024

Abstract The treatment of brain diseases has always been the focus attention. Due to presence blood‐brain barrier (BBB), most small molecule drugs are difficult reach brain, leading undesirable therapeutic outcomes. Recently, nanomedicines that can cross BBB and precisely target lesion sites have emerged as thrilling tools enhance early diagnosis treat various intractable disorders. Extensive research shown reactive oxygen species (ROS) play a crucial role in occurrence progression diseases, including tumors neurodegenerative (NDDs) such Alzheimer's disease, Parkinson's stroke, or traumatic injury, making ROS potential target. In this review, on structure function well mechanisms first elaborated through which nanomedicine traverses it. Then, recent studies production summarized photodynamic therapy (PDT), chemodynamic (CDT), sonodynamic (SDT) for treating tumors, depletion NDDs. This provides valuable guidance future design ROS‐targeted disease treatment. ongoing challenges perspectives developing nanomedicine‐based management also discussed outlined.

Language: Английский

Citations

2

Harnessing Bimetallic Imwa Nanosensitizer to Unleash Ferroptosis and Calcium Overload: Unlocking Tumor Vulnerability for Potentiated Imwa Therapy Against Hepatocellular Carcinoma DOI
Guanhua Qiu, Duo Wang, Peihan Xie

et al.

Published: Jan. 1, 2024

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Language: Английский

Citations

1

Harnessing bimetallic iMWA nanosensitizer to unleash ferroptosis and calcium overload: Unlocking tumor vulnerability for potentiated iMWA therapy against hepatocellular carcinoma DOI
Guanhua Qiu, Duo Wang, Peihan Xie

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 495, P. 153368 - 153368

Published: June 21, 2024

Language: Английский

Citations

1

Inhibition of Transmural Inflammation in Crohn’s Disease by Orally Administered Tumor Necrosis Factor-Alpha Deoxyribozymes-Loaded Pyroptosis Nanoinhibitors DOI
Zhun Li, Zhenxing Zhu,

Dongtao Zhou

et al.

ACS Applied Materials & Interfaces, Journal Year: 2024, Volume and Issue: 16(31), P. 40499 - 40514

Published: July 25, 2024

Crohn's disease (CD) is a refractory chronic inflammatory bowel (IBD) with unknown etiology. Transmural inflammation, involving the intestine and mesentery, represents characteristic pathological feature of CD serves as critical contributor to its intractability. Here, this study describes an oral pyroptosis nanoinhibitor loaded tumor necrosis factor-α (TNF-α) deoxyribozymes (DNAzymes) (DNAzymes@degradable silicon nanoparticles@Mannose, Dz@MDSN), which can target macrophages at site inflammation respond reactive oxygen species (ROS) release drugs. Dz@MDSN not only break cycle in by degrading TNF-α mRNA but also reduce production ROS mainly from macrophages. Moreover, inhibits excessive epithelial cells through clearance, thereby repairing intestinal barrier reducing translocation bacteria mesentery. Consequently, these combined actions synergistically contribute suppression within both This likely first successful attempt field utilizing nanomaterials achieve transmural healing for CD, provides promising treatment strategy patients.

Language: Английский

Citations

1

Folic Acid-Functionalized β-Cyclodextrin for Delivery of Organelle-Targeted Peptide Chemotherapeutics in Cancer DOI

Hae Won Ok,

Seongeon Jin,

Gaeun Park

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(9), P. 4498 - 4509

Published: July 29, 2024

Recent emphasis on the design of drug delivery systems typically involves effective transport a pharmaceutical substance to disease site with desired therapeutic efficacy and minimal cytotoxicity. Organelle-targeted peptides have become an integral part designing important class prodrug/prodrug assemblies for new supramolecular therapeutics owing their favorable biocompatibility, synthetic ease, tunability aggregation behavior, functionalization site-specificity. However, it is still limited due low selectivity. We designed folic acid-functionalized β-cyclodextrin (FA-CD) as platform specific selective organelle-targeted (such microtubule, lysosome, mitochondria) peptide chemotherapeutics folate receptor (FR) overexpressing cancer cell lines. Low toxicity was found FA-CD inclusion complex in FR-negative normal cells, but superior inhibition tumor growth no vivo xenograft model.

Language: Английский

Citations

1